The estimated Net Worth of Biochem Incshire Pharmaceut... is at least $29.1 Milion dollars as of 2 June 2004. Biochem Pharmaceut owns over 4,030,000 units of Immunogen stock worth over $2,064,902 and over the last 20 years Biochem sold IMGN stock worth over $27,041,300.
Biochem has made over 1 trades of the Immunogen stock since 2004, according to the Form 4 filled with the SEC. Most recently Biochem sold 4,030,000 units of IMGN stock worth $27,041,300 on 2 June 2004.
The largest trade Biochem's ever made was selling 4,030,000 units of Immunogen stock on 2 June 2004 worth over $27,041,300. On average, Biochem trades about 4,030,000 units every 0 days since 2004. As of 2 June 2004 Biochem still owns at least 66,098 units of Immunogen stock.
You can see the complete history of Biochem Pharmaceut stock trades at the bottom of the page.
Over the last 21 years, insiders at Immunogen have traded over $72,947,831 worth of Immunogen stock and bought 303,125 units worth $974,603 . The most active insiders traders include Biochem Incshire Pharmaceut..., Capital, L.P.Morton Holding... oraz Mark J Enyedy. On average, Immunogen executives and independent directors trade stock every 34 days with the average trade being worth of $2,554,057. The most recent stock trade was executed by Stacy Ann Coen on 2 February 2024, trading 14,350 units of IMGN stock currently worth $448,294.
immunogen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (adc) technology. the company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. leading healthcare companies have licensed rights to use immunogen's technology to develop novel anticancer therapies, and roche's marketed product, kadcyla, utilizes immunogen's adc technology. more information about the company can be found at www.immunogen.com.
Immunogen executives and other stock owners filed with the SEC include: